The topic of coexisting aortic stenosis (AS) and cardiac amyloidosis (CA) has become a classic of contemporary cardiology due to the spread of transcatheter aortic valve replacement (TAVR) as a treatment for AS and the wide availability of bone scintigraphy as a non-invasive diagnostic standard for transthyretin-related amyloidosis (ATTR).
Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle?
Rapezzi C.
Primo
;Campo G.Ultimo
2021
Abstract
The topic of coexisting aortic stenosis (AS) and cardiac amyloidosis (CA) has become a classic of contemporary cardiology due to the spread of transcatheter aortic valve replacement (TAVR) as a treatment for AS and the wide availability of bone scintigraphy as a non-invasive diagnostic standard for transthyretin-related amyloidosis (ATTR).File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
European J of Heart Fail - 2020 - Rapezzi.pdf
solo gestori archivio
Descrizione: versione editoriale
Tipologia:
Full text (versione editoriale)
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
503.78 kB
Formato
Adobe PDF
|
503.78 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
